PPARA and metabolic syndrome: Selective PPAR modulators (SPPARMS), such as the highly potent and selective PPAR-α agonist K-877, have already shown some promise in treating dyslipidemias and insulin resistance with favorable adverse effect profiles compared to approved drugs such as fenofibrate [53].